Company intelligence / Profile preview

PRO

Seattle, Washington, United States

Ownership: Private
Employees: ~100
Development stage: Other

Overview

ProfoundBio is a clinical-stage biotechnology company focused on developing next-generation antibody-drug conjugates (ADCs) and other antibody-based therapeutics for the treatment of cancer. The company utilizes proprietary linker-payload platforms designed to improve the therapeutic index of ADCs by enhancing stability in circulation and increasing potency within the tumor microenvironment. Its lead candidate, rinatabart sesutecan (PRO1184), is a folate receptor alpha-targeted ADC currently in Phase 2 clinical trials for various solid tumors. In May 2024, ProfoundBio was acquired by Genmab for $1.8 billion to strengthen Genmab's oncology pipeline and ADC capabilities.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibody
Industry: Biotech

Partnerships

Genmab

Beyond the preview

Go deeper on PRO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRO.

Explore the full profile